Related Experiment Video
Updated: Jul 6, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Factor IX gene therapy for hemophilia.
1Expression Genetics, Inc., Huntsville, AL, USA.
Methods in Molecular Biology (Clifton, N.J.)
|March 29, 2008
Summary
Gene therapy for hemophilia B using plasmid DNA and electroporation offers an effective alternative to viral vectors. This novel method achieves high factor IX levels after a single treatment, overcoming immune response limitations.
Area of Science:
- Biotechnology
- Gene Therapy
- Molecular Medicine
Background:
- Viral vectors for gene therapy in hemophilia B are limited by immune responses.
- Systemic delivery of human factor IX (FIX) is crucial for hemophilia B treatment.
Purpose of the Study:
- To develop a non-viral gene therapy approach for hemophilia B.
- To evaluate the efficacy of in vivo electroporation for delivering plasmid DNA encoding FIX.
Main Methods:
- Intramuscular injection of plasmid DNA formulated with an anionic polymer.
- In vivo electroporation to enhance DNA delivery and transfection.
- Measurement of systemic levels of human factor IX protein.
Main Results:
- High transfection efficiency achieved with the novel method.
- Sustained high levels of systemic human factor IX protein produced.
- Successful treatment following a single administration.
Conclusions:
- Non-viral gene therapy using plasmid DNA and electroporation is a viable alternative for hemophilia B.
- This method overcomes limitations associated with viral vector delivery systems.
- A single administration can lead to effective therapeutic levels of factor IX.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.